{
  "term": "Upadacitinib",
  "role": "concept",
  "parent_concepts": [
    "Medicine"
  ],
  "layer": 5,
  "domain": "PhysicalWorld",
  "definition": "Upadacitinib, sold under\nthe brand name &%Rinvoq, is a Janus kinase (JAK) inhibitor medication\nfor the treatment of moderately to severely active\n&%RheumatoidArthritis in adults where methotrexate (a drug used to\ntreat active arthritis) did not work well or could not be tolerated.\nIt was developed by the biotech company &%AbbVie. Common side effects\ninclude upper respiratory tract infections (common cold, sinus\ninfections), &%Nausea, &%Cough, and &%Fever.[from Wikipedia]",
  "definition_source": "SUMO",
  "aliases": [
    "upadacitinib"
  ],
  "wordnet": {
    "synsets": [
      "upadacitinib.n.01"
    ],
    "canonical_synset": "upadacitinib.n.01",
    "lemmas": [
      "upadacitinib"
    ],
    "pos": "noun"
  },
  "relationships": {
    "related": [],
    "antonyms": [],
    "has_part": [
      "Rinvoq"
    ],
    "part_of": []
  },
  "safety_tags": {
    "risk_level": "low",
    "impacts": [],
    "treaty_relevant": false,
    "harness_relevant": false
  },
  "training_hints": {
    "positive_examples": [],
    "negative_examples": [],
    "disambiguation": "",
    "seed_terms": [
      "upadacitinib"
    ]
  },
  "children": [
    "Rinvoq"
  ],
  "is_category_lens": true,
  "child_count": 1
}